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Abstract
Breast neuroendocrine tumours are rare, accounting for up to 5% of all breasts tumours and approximately 1% of all neuroendocrine 
tumours. In most cases, breast neuroendocrine tumours are histologically and moderately well differentiated. Neuroendocrine breast 
tumours lack characteristic imaging patterns. The histopathological assessment of these tumours is difficult, and in most cases the correct 
diagnosis is made after proper examination of the postsurgical specimen. (Endokrynol Pol 2017; 68 (5): 597–602)
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Streszczenie
Guzy neuroendokrynne piersi są rzadkimi nowotworami, stanowią do 5% guzów piersi i około 1% wszystkich guzów neuroendokrynnych. 
Większość zmian jest dobrze i umiarkowanie zróżnicowana, jednak w badaniach obrazowych trudno wskazać cechy morfologiczne, które 
byłyby charakterystyczne dla tej grupy nowotworów. Ocena histopatologiczna również jest trudna i najczęściej właściwe rozpoznanie 
stawiane jest dopiero na podstawie materiału pooperacyjnego. (Endokrynol Pol 2017; 68 (5): 597–602)
Słowa kluczowe: guz neuroendokrynny piersi
Introduction
Neuroendocrine tumours (NET) constitute a large 
and heterogeneous group of rare neoplasms with 
non-specific clinical symptoms, frequently originating 
from the GI tract (bowel and pancreas) and respiratory 
system [1, 2], and less frequent from endocrine glands 
(adrenals, thyroid, hypophysis, thalamus) [3]. The 
usual form is a singular lesion, and sporadically they 
contribute in MEN syndromes (multiple endocrine 
neoplasia).
The primary neuroendocrine tumours of the breast 
were not separately classified by the WHO until 2003 
and account for 0.1% [4] to 5% [5, 6] of breast tumours 
and approximately 1% of all neuroendocrine tumours.
According to the WHO modification from 2012 [7, 8], 
neuroendocrine tumours are divided into the following 
groups: well differentiated, poorly differentiated (small 
cell), and cancers with neuroendocrine differentiation [4]. 
A local accumulation of neuroendocrine cells is present 
in many sub-types of breast cancers [9].
The definition of primary neuroendocrine breast 
tumour is reserved for cases with over 50% of neoplastic 
cells showing expression of the markers typical for these 
tumours: chromogranin and synaptophysin [9].
The majority of tumours are well or moderately 
differentiated. Over 50% of the poorly differentiated 
tumours are positive for oestrogen and progesterone 
receptors [7].
The differentiation between primary and secondary 
neuroendocrine carcinoma of the breast is possible only 
after the other primary site is excluded [4].
Description of the cases
Patient no. 1 
A 65-year-old woman with palpable tumour of the 
left breast. In spectral mammography, there was an 
8 x 4-cm mass with strong contrast enhancement in the 
in lower quadrants of the left breast (Figure 1A, 1B). 
A BLESS biopsy under mammographic guidance 
revealed invasive ductal carcinoma G3. The patient 
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underwent mastectomy, and the final pathology report 
revealed the neuroendocrine tumour with small foci of 
connective tissue infiltration (Figure 1C). The size of the 
tumour was 5 x 1.7 x 1.5 cm, and the tumour was posi-
tive for oestrogen and progesterone receptors, Her-2 
negative, Ki 67 1%, synaptophysin (+), and chromogran 
(–). The axillary lymph nodes were negative.
Patient no. 2 
A 77-year-old woman after positive FNA of the left 
breast under US guidance, referred for a mammogra-
phy, which revealed and oval, 31 x 22-mm lesion with 
microlobular and somewhat spiculated margins in the 
upper outer quadrant of the left breast (Figure 2A, 2B). 
The core biopsy under US guidance revealed invasive 
ductal carcinoma. After the BCU meeting decision the 
patient was referred for a mastectomy. The pathologic 
examination revealed a grey, solid tumour 2.7 x 2 x 1.9 
cm with final description as the neuroendocrine ductal 
carcinoma G2 (Figure 2C — multifocal neuroendocrine 
tumour with infiltration on fat tissue H-E stain, Figure 
2D — synaptophysin stain) with positive progesterone 
and oestrogen receptors, Her-2 negative, and Ki 67 posi-
tive in 10%. The axillary lymph nodes were negative.
Patient no. 3. 
A 52-year-old woman with positive US examination 
of the left breast. The spectral mammography showed 
3.9 x 2.2 cm strongly enhancing mass in the upper 
outer quadrant of the left breast. Behind the dominant 
Figure 1A, B. Spectral mammography: Neuroendocrine tumour of 
the breast; C. Neuroendocrine tumour with small foci of connective 
tissue infiltration; H-E, 40x
Rycina 1A, B. Mammografia spektralna — guz neuroendokrynny 
piersi; C. Guz neuroendokrynny z drobnoogniskowym naciekiem 
tkanki łącznej 40x H-E
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mass the mammography revealed a second, similar 
but smaller 2.5 x 1.3-cm lesion (Figure 3A, 3B). The core 
biopsy of the dominant mass revealed invasive ductal 
carcinoma G2. The patient underwent mastectomy, and 
the post-surgical diagnosis was invasive ductal carci-
noma with focal neuroendocrine differentiation and 
focal mucinous differentiation (Figure 3C — H-E stain, 
Figure 3D — synaptophysin stain). The cancer was 
positive for progesterone and oestrogen receptors, 
Her-2 negative, Ki67 positive in 15%, and synaptophy-
sin positive. The axillary lymph nodes were negative.
Patient no. 4. 
A 65-year-old woman with positive US examination 
of the left breast. The spectral mammography showed 
enhancing, spiculated tumour in the upper outer quad-
rant, measuring 2.5 x 2.2 cm, with intense desmoplastic 
reaction on the area of 3–3.5 cm (Figure 4A, 4B). The core 
biopsy of the tumour, performed in a different hospital, 
showed invasive ductal carcinoma G2. The BCU meet-
ing referred the patient for conserving breast treatment. 
The radiograph of the specimen (Figure 4C) shows 
the excised tumour. The final pathological diagnosis 
Figure 2A, B. Spectral mammography: Multifocal neuroendocrine tumour of the breast; C. Multifocal neuroendocrine tumour infiltrating 
fatty tissue; H-E, 40x; D. Multifocal neuroendocrine tumour infiltrating fatty tissue; synaptophysin, 40x
Rycina 2A, B. Mammografia spektralna — guz neuroendokrynny piersi wieloogniskowy; C. Wieloogniskowy guz neuroendokrynny 
z naciekiem tkanki tłuszczowej H-E 40x; D. Wieloogniskowy guz neuroendokrynny z naciekiem tkanki tłuszczowej — synaptofizyna 40x
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was neuroendocrine tumour NET G2 (Figure 4D) with 
positive progesterone and oestrogen receptors, Her-2 
negative, Ki67 5%, synaptophysin (+), chromogranin 
(+), and serotonin (-). The axillary lymph nodes were 
negative.
Discussion
Primary neuroendocrine breast tumours are extremely 
rare, with no typical clinical symptoms, and the diagnosis 
of the primary tumour is always done by exclusion [4]. 
Older women, in their 60s and 70s, are more affected, 
commonly one decade later than invasive breast cancer 
[10]. From 10 to 50% of the breast tumours can contain 
dispersed singular neuroendocrine cells; it is important 
is to distinguish cancer with focal neuroendocrine dif-
ferentiation from “proper” neuroendocrine tumours 
[5]. In the literature, there are no cases of benign 
neuroendocrine tumours of the breast [6], thus one 
hypothesis suggests that they originate as a result of 
Figure 3A, B. Spectral mammography: Invasive carcinoma NST G2 with focal neuroendocrine differentiation; C. Invasive carcinoma 
NST G2 with focal neuroendocrine differentiation; H-E, 40x; D. Invasive carcinoma NST G2 with focal neuroendocrine differentiation; 
synaptophysin, 100x
Rycina 3A, B. Mammografia spektralna — rak inwazyjny NST GII z ogniskowym zróżnicowaniem neuroendokrynnym; C. Rak 
inwazyjny NST GII z ogniskowym zróżnicowaniem neuroendokrynnym H-E 40x; D. Rak inwazyjny NST GII z ogniskowym 
zróżnicowaniem neuroendokrynnym — synaptofizyna 100x
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the differentiation of the breast cancer and not directly 
from preserved endocrine cells [9]. 
Most neuroendocrine cells coexist with invasive 
ductal cancer or cancer with mucinous component, 
and typically tumours show expression of oestrogen 
and progesterone receptors (4.10)
The specific radiological symptoms are still ques-
tioned. According to Park [2], in mammographic evalu-
Figure 4A, B. Spectral mammography: Neuroendocrine tumour NET G2; C. Intraoperative mammography of the specimen; 
D. Neuroendocrine tumour NET G2; chromogranin (+), 100x
Rycina 4A, B. Mammografia spektralna — guz neuroendokrynny NET G2; C. Mammografia śródoperacyjna preparatu; D. Guz 
neuroendokrynny NET G2 — chromogranina (+) 100x
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ation the neuroendocrine tumour was most frequently 
described as a mass (82%) with no calcifications in 75% 
of cases. Most tumours were oval, round, or lobular 
(70%). In our material, three of the four lesions were 
morphologically similar and the margins were poorly 
defined. According to Park [2], spiculated margins, 
considered as a radiological sign of malignancy, were 
present only in 22% of lesions; similarly, in our cases 
only one in four had spiculated margins. However, in 
accessible case descriptions there are no specific features 
of NEC in the radiological imaging (6.10).
The retrospective analysis of a large group of 
patients (142 persons) performed by Wang et al. [10] 
revealed that neuroendocrine tumours at the time of 
the diagnosis are larger than invasive cancers (over 
20 mm) and more frequently have metastases to the 
lymph nodes. In our material, the lesions were bigger 
than 2 cm in all four patients, but no preoperative FNA 
showed dissemination to the lymph nodes, although 
all the patients were qualified for sentinel lymph node 
procedure. In histopathological material also no dis-
semination to lymph nodes was found. In every case, 
tests for hormonal receptors confirmed expression of 
PR and E receptors. 
Neuroendocrine tumours and cancer with neuroen-
docrine differentiation according to WHO classification 
are included to the special sub-types of breast neo-
plasms. The pathologic assessment of neuroendocrine 
tumours can be challenging in cases where the material 
has been obtained by core biopsy. The morphological 
characteristics of the neuroendocrine cancer cell, espe-
cially of the pseudo adenomatous form, is very similar 
to invasive NST cancer. The assessment of hormone 
receptors and Her-2 protein carried out by core biopsy 
in invasive cancers adds no value to diagnosis because 
both NST G1/G2 and neuroendocrine tumours are 
hormonally positive and Her-2 negative. Positive Her-
2 could indicate invasive NST cancer. The diagnosis of 
the neuroendocrine tumour is based on immunohis-
tochemical positive reaction of chromogranin A and/ 
/or synaptophysin.
The finding in a postoperative specimen of solid or 
lobular foci arranged in nests entwined by a narrow 
layer of connective tissue with cells of bright cytoplasm 
and bright chromatin with nucleolus indicates suspicion 
of neuroendocrine tumour, requiring immunohisto-
chemical confirmation. 
The Ki 67 proliferative index allows differentiation 
of neuroendocrine tumours (Ki 67 up to 20%) from 
neuroendocrine cancers (Ki 67 over 20%).
Sometimes, poorly differentiated neuroendocrine 
breast cancer is morphologically very similar to small 
cell lung neuroendocrine cancer, and in those cases is 
called small cell neuroendocrine cancer.
It should not be forgotten that in some cases the 
breast is a metastatic destination for neuroendocrine 
cancer of the lung and GI tract. In such cases in the 
histopathological examination, apart from positive 
neuroendocrine markers, positive antibodies CD56 
(lung) and serotonin (GI tract) could be helpful. In the 
case of the papillary cancer the neuroendocrine mark-
ers could be also positive. In such cases neoplastic cells 
are small with hyperchromatic fusiform or multiform 
nuclei and lay in foci with intense desmoplastic reac-
tion. The foci can be surrounded by a layer of myoepi-
thelial cells. Steroid receptors are usually positive and 
Her 2-protein negative. Positive cytokeratin 8 and 18 
can be helpful, but the morphology of the routinely 
stained sample decides on the final diagnosis of cancer.
Neuroendocrine breast cancers are a small group of 
neoplasms with different degrees of malignancy, thus 
the prognosis differs. It should be noted that they can 
be primary or secondary. In order to establish proper 
diagnosis a multidisciplinary approach is mandatory, 
with a special role played by immunohistochemical 
tests.
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